Hope S. Rugo

100.3k total citations · 42 hit papers
847 papers, 45.2k citations indexed

About

Hope S. Rugo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hope S. Rugo has authored 847 papers receiving a total of 45.2k indexed citations (citations by other indexed papers that have themselves been cited), including 665 papers in Oncology, 464 papers in Pulmonary and Respiratory Medicine and 214 papers in Cancer Research. Recurrent topics in Hope S. Rugo's work include Advanced Breast Cancer Therapies (385 papers), Cancer Treatment and Pharmacology (280 papers) and HER2/EGFR in Cancer Research (252 papers). Hope S. Rugo is often cited by papers focused on Advanced Breast Cancer Therapies (385 papers), Cancer Treatment and Pharmacology (280 papers) and HER2/EGFR in Cancer Research (252 papers). Hope S. Rugo collaborates with scholars based in United States, France and Spain. Hope S. Rugo's co-authors include Véronique Dièras, Hiroji Iwata, Eric P. Winer, Sherene Loi, Seock‐Ah Im, Peter Schmid, Lisa M. Coussens, Carlos H. Barrios, Sylvia Adams and Leisha A. Emens and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Hope S. Rugo

802 papers receiving 44.5k citations

Hit Papers

Atezolizumab and Nab-Paclitaxel ... 2005 2026 2012 2019 2018 2016 2019 2018 2011 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    2018 3.0k citations Peter Schmid, Sylvia Adams et al. New England Journal of Medicine profile →
  2. Palbociclib and Letrozole in Advanced Breast Cancer
    2016 1.9k citations Hope S. Rugo, Seock‐Ah Im et al. New England Journal of Medicine profile →
  3. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
    2019 1.6k citations Fabrice André, Sibylle Loibl et al. New England Journal of Medicine profile →
  4. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
    2018 1.4k citations Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine profile →
  5. Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
    2011 1.3k citations Hope S. Rugo et al. profile →
  6. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
    2005 1.0k citations Kathy D. Miller, Hope S. Rugo et al. Journal of Clinical Oncology profile →
  7. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
    2019 846 citations Peter Schmid, Hope S. Rugo et al. The Lancet Oncology profile →
  8. Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells
    2014 758 citations Hope S. Rugo et al. profile →
  9. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
    2010 701 citations Hope S. Rugo, Joyce O’Shaughnessy et al. Journal of Clinical Oncology profile →
  10. Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
    2017 662 citations Hope S. Rugo et al. CA A Cancer Journal for Clinicians profile →
  11. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
    2018 656 citations Hope S. Rugo et al. Journal of Clinical Oncology profile →
  12. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    2019 599 citations Aditya Bardia, Ingrid A. Mayer et al. New England Journal of Medicine profile →
  13. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
    2022 594 citations Javier Cortés, Hope S. Rugo et al. New England Journal of Medicine profile →
  14. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
    2010 568 citations Hope S. Rugo, Ian E. Krop et al. Journal of Clinical Oncology profile →
  15. The cancer glycocalyx mechanically primes integrin-mediated growth and survival
    2014 520 citations Hope S. Rugo et al. profile →
  16. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
    2018 516 citations Sibylle Loibl, Joyce O’Shaughnessy et al. The Lancet Oncology profile →
  17. Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
    2009 504 citations Hope S. Rugo et al. Journal of Clinical Oncology profile →
  18. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
    2017 490 citations Sara M. Tolaney, Hope S. Rugo et al. profile →
  19. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
    2018 460 citations Sylvia Adams, Sherene Loi et al. Annals of Oncology profile →
  20. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    2015 458 citations Sara M. Tolaney, Denise A. Yardley et al. New England Journal of Medicine profile →
  21. Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
    2016 446 citations Hope S. Rugo et al. Journal of Clinical Oncology profile →
  22. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
    2014 407 citations Martine Piccart, Hope S. Rugo et al. Annals of Oncology profile →
  23. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
    2017 386 citations Hope S. Rugo et al. Journal of Clinical Oncology profile →
  24. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
    2013 383 citations Denise A. Yardley, Martine Piccart et al. profile →
  25. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
    2017 377 citations Hope S. Rugo et al. Journal of Clinical Oncology profile →
  26. Management of Cancer Cachexia: ASCO Guideline
    2020 373 citations Hope S. Rugo et al. Journal of Clinical Oncology profile →
  27. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
    2020 371 citations Fabrice André, Sibylle Loibl et al. Annals of Oncology profile →
  28. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies
    2020 335 citations Hope S. Rugo et al. profile →
  29. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
    2018 302 citations Hope S. Rugo et al. Journal of Clinical Oncology profile →
  30. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
    2021 293 citations Leisha A. Emens, Sylvia Adams et al. Annals of Oncology profile →
  31. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
    2019 286 citations Hope S. Rugo, Véronique Dièras et al. profile →
  32. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
    2020 252 citations Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology profile →
  33. An Overview of PARP Inhibitors for the Treatment of Breast Cancer
    2021 241 citations Hope S. Rugo et al. profile →
  34. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
    2021 223 citations Hope S. Rugo, Patrick Neven et al. The Lancet Oncology profile →
  35. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
    2023 210 citations Hope S. Rugo, Aditya Bardia et al. profile →
  36. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
    2021 205 citations Leisha A. Emens, Luciana Molinero et al. JNCI Journal of the National Cancer Institute profile →
  37. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
    2022 176 citations Hope S. Rugo, Aditya Bardia et al. Journal of Clinical Oncology profile →
  38. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
    2022 114 citations Hope S. Rugo, Seock‐Ah Im et al. profile →
  39. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
    2022 109 citations Hope S. Rugo, Véronique Dièras et al. Journal of Clinical Oncology profile →
  40. Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
    2023 96 citations Laura A. Huppert, Hope S. Rugo et al. CA A Cancer Journal for Clinicians profile →
  41. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
    2024 81 citations Véronique Dièras, Hope S. Rugo et al. Journal of Clinical Oncology profile →
  42. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
    2024 71 citations Aditya Bardia, Hope S. Rugo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hope S. Rugo United States 90 31.3k 16.6k 11.5k 11.2k 6.2k 847 45.2k
Fabrice André France 95 20.5k 0.7× 13.0k 0.8× 14.1k 1.2× 13.9k 1.2× 4.8k 0.8× 675 38.0k
Seock‐Ah Im South Korea 70 23.9k 0.8× 14.0k 0.8× 9.0k 0.8× 7.2k 0.6× 2.7k 0.4× 661 32.9k
José Baselga United States 98 25.8k 0.8× 14.1k 0.9× 9.8k 0.8× 19.7k 1.8× 2.6k 0.4× 484 46.7k
Massimo Cristofanilli United States 89 26.3k 0.8× 11.8k 0.7× 18.6k 1.6× 9.7k 0.9× 2.4k 0.4× 600 38.3k
Eric P. Winer United States 118 36.8k 1.2× 14.4k 0.9× 20.2k 1.8× 10.7k 1.0× 3.7k 0.6× 737 56.6k
Kenneth J. Pienta United States 116 18.0k 0.6× 17.5k 1.1× 12.1k 1.0× 21.8k 1.9× 7.2k 1.2× 675 49.8k
Martine Piccart Belgium 102 27.4k 0.9× 9.2k 0.6× 16.4k 1.4× 12.8k 1.1× 3.2k 0.5× 836 42.9k
Roy S. Herbst United States 102 31.9k 1.0× 26.5k 1.6× 9.2k 0.8× 17.0k 1.5× 5.5k 0.9× 583 50.9k
Nadia Harbeck Germany 85 20.5k 0.7× 12.1k 0.7× 13.2k 1.1× 8.8k 0.8× 1.7k 0.3× 855 33.6k
Jean‐Charles Soria France 95 19.7k 0.6× 12.8k 0.8× 6.8k 0.6× 13.0k 1.2× 4.7k 0.8× 679 34.8k

Countries citing papers authored by Hope S. Rugo

Since Specialization
Citations

This map shows the geographic impact of Hope S. Rugo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hope S. Rugo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hope S. Rugo more than expected).

Fields of papers citing papers by Hope S. Rugo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hope S. Rugo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hope S. Rugo. The network helps show where Hope S. Rugo may publish in the future.

Co-authorship network of co-authors of Hope S. Rugo

This figure shows the co-authorship network connecting the top 25 collaborators of Hope S. Rugo. A scholar is included among the top collaborators of Hope S. Rugo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hope S. Rugo. Hope S. Rugo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meric‐Bernstam, Funda, Aditya Bardia, Paolo Bossi, et al.. (2025). Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.. PubMed. 30(3). 1 indexed citations
2.
Ríos-Hoyo, Alejandro, Erin F. Cobain, Laura A. Huppert, et al.. (2024). Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer. Journal of Clinical Oncology. 42(22). 2632–2636. 10 indexed citations
3.
4.
Bardia, Aditya, Hope S. Rugo, Sara M. Tolaney, et al.. (2024). Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of Clinical Oncology. 42(15). 1738–1744. 71 indexed citations breakdown →
5.
6.
Cescon, David W., Peter Schmid, Hope S. Rugo, et al.. (2023). Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. JNCI Journal of the National Cancer Institute. 116(5). 717–727. 7 indexed citations
7.
Donohue, James F., J.S. Elborn, Peter Lansberg, et al.. (2023). Bridging the “Know-Do” Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science. Journal of Healthcare Leadership. Volume 15. 103–119. 17 indexed citations
8.
Corti, Chiara, Gabriele Antonarelli, Carmine Valenza, et al.. (2022). Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?. European Journal of Cancer. 171. 25–42. 13 indexed citations
9.
Cortés, Javier, Hope S. Rugo, David W. Cescon, et al.. (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 387(3). 217–226. 594 indexed citations breakdown →
10.
Emens, Leisha A., Sylvia Adams, Carlos H. Barrios, et al.. (2021). First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of Oncology. 32(8). 983–993. 293 indexed citations breakdown →
11.
Turner, Stuart, Stephen Chia, Hemanth Kanakamedala, et al.. (2021). Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, PIK3CA-Mutated Breast Cancer. The Oncologist. 26(7). e1133–e1142. 23 indexed citations
12.
Cinar, Pelin, Richard J. Bold, Daniela A. Bota, et al.. (2020). Planning for post‐pandemic cancer care delivery: Recovery or opportunity for redesign?. CA A Cancer Journal for Clinicians. 71(1). 34–46. 14 indexed citations
13.
Rugo, Hope S., Aditya Bardia, Sara M. Tolaney, et al.. (2020). TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer. Future Oncology. 16(12). 705–715. 89 indexed citations
14.
Rugo, Hope S., Lasika Seneviratne, J. Thaddeus Beck, et al.. (2017). Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. The Lancet Oncology. 18(5). 654–662. 145 indexed citations
15.
Dranitsaris, George, Stefan Glück, Claudio Faria, David L. Cox, & Hope S. Rugo. (2014). Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting. Clinical Therapeutics. 37(1). 134–144. 13 indexed citations
16.
Yardley, Denise A., Debu Tripathy, Adam Brufsky, et al.. (2014). Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. British Journal of Cancer. 110(11). 2756–2764. 51 indexed citations
17.
18.
Glencer, Alexa, et al.. (2012). Everolimus and Its Role in Hormone-Resistant and Trastuzumab-Resistant Metastatic Breast Cancer. Future Oncology. 8(11). 1383–1396. 10 indexed citations
19.
Melisko, Michelle, et al.. (2008). Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. Journal of Neuro-Oncology. 88(3). 359–365. 58 indexed citations
20.
Melisko, Michelle, Michael Glantz, & Hope S. Rugo. (2008). New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nature Clinical Practice Oncology. 6(1). 25–33. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fabrice André Breakdown of academic impact, for papers by Seock‐Ah Im Breakdown of academic impact, for papers by José Baselga Breakdown of academic impact, for papers by Massimo Cristofanilli Breakdown of academic impact, for papers by Eric P. Winer Breakdown of academic impact, for papers by Kenneth J. Pienta Breakdown of academic impact, for papers by Martine Piccart Breakdown of academic impact, for papers by Roy S. Herbst Breakdown of academic impact, for papers by Nadia Harbeck Breakdown of academic impact, for papers by Jean‐Charles Soria
Rankless by CCL
2026